

John G Kuruvilla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5323376/publications.pdf>

Version: 2024-02-01

99
papers

5,907
citations

236612

25
h-index

76769

74
g-index

118
all docs

118
docs citations

118
times ranked

6974
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 590-599.	2.5	10
2	Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>EJHaem</i> , 2022, 3, 139-153.	0.4	4
3	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. <i>Cancers</i> , 2022, 14, 791.	1.7	2
4	Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma. <i>EJHaem</i> , 2022, 3, 394-405.	0.4	7
5	Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume. <i>American Journal of Hematology</i> , 2022, 97, 583-591.	2.0	7
6	Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor – a retrospective, single center study. <i>Leukemia and Lymphoma</i> , 2022, , 1-8.	0.6	1
7	An evaluation of pembrolizumab for classical Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2022, 15, 285-293.	1.0	1
8	Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. <i>EJHaem</i> , 2022, 3, 223-227.	0.4	0
9	Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 512-524.	5.1	144
10	Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy. <i>Bone Marrow Transplantation</i> , 2021, 56, 2400-2409.	1.3	7
11	Pembrolizumab for relapsed or refractory Hodgkin lymphoma – Author's reply. <i>Lancet Oncology</i> , The, 2021, 22, e235.	5.1	0
12	Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021, 195, 388-398.	1.2	47
13	Computerized cognitive training in post-treatment hematological cancer survivors: a feasibility study. <i>Pilot and Feasibility Studies</i> , 2021, 7, 36.	0.5	6
14	Evolving management strategies for lymphomas during the COVID-19 pandemic. <i>Leukemia and Lymphoma</i> , 2021, 62, 1046-1056.	0.6	2
15	Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience. <i>Blood</i> , 2021, 138, 2525-2525.	0.6	2
16	Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume. <i>Blood</i> , 2021, 138, 1383-1383.	0.6	0
17	Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study. <i>Blood</i> , 2021, 138, 3574-3574.	0.6	5
18	Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation. <i>Blood</i> , 2021, 138, 3055-3055.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Radiotherapy in mantle cell lymphoma: A literature review. <i>Hematological Oncology</i> , 2020, 38, 223-228.	0.8	4
20	Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL). <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 15-21.	1.9	15
21	A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score. <i>Blood Advances</i> , 2020, 4, 5762-5771.	2.5	3
22	Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience. <i>Leukemia and Lymphoma</i> , 2020, 61, 3014-3017.	0.6	2
23	Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2153-2160.	0.6	1
24	Developing anti-CD19 antibody-based combinations in lymphoma. <i>Lancet Oncology</i> , The, 2020, 21, 870-872.	5.1	2
25	Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Haematology</i> .the, 2020, 7, e100-e111.	2.2	59
26	Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy. <i>Blood</i> , 2020, 136, 12-12.	0.6	4
27	Treatment approaches in relapsed or refractory peripheral T-cell lymphomas. <i>F1000Research</i> , 2020, 9, 1091.	0.8	8
28	A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing ≥ 70 kg. <i>Bone Marrow Transplantation</i> , 2019, 54, 258-264.	1.3	1
29	Significance of treatment response when managing patients with primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 349-357.	0.6	3
30	Optimal management of mantle cell lymphoma in the primary setting. <i>Expert Review of Hematology</i> , 2019, 12, 715-721.	1.0	0
31	Pembrolizumab for the treatment of diffuse large B-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1119-1126.	1.4	14
32	Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 2576-2579.	0.6	0
33	A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study. <i>Leukemia and Lymphoma</i> , 2019, 60, 912-919.	0.6	18
34	A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 4095-4095.	0.6	8
35	Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 243-243.	0.6	42
36	Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial. <i>Blood</i> , 2019, 134, 875-875.	0.6	1

#	ARTICLE	IF	CITATIONS
37	The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of Overall Survival. <i>Blood</i> , 2019, 134, 1559-1559.	0.6	0
38	Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma. <i>Blood</i> , 2019, 134, 2027-2027.	0.6	0
39	Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review. <i>BMJ Open</i> , 2018, 8, e017578.	0.8	5
40	Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 347-351.	1.3	1
41	Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2018, 19, 257-266.	5.1	89
42	Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 757-760.	1.2	13
43	Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. <i>Blood</i> , 2018, 131, 182-190.	0.6	130
44	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1428-1439.	0.8	551
45	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 942-950.	0.8	273
46	Optimal frontline management of mantle cell lymphoma: can we agree?. <i>Expert Review of Hematology</i> , 2018, 11, 911-914.	1.0	1
47	Functional Predictors of Chemotherapy Toxicity in Elderly Lymphoma Patients: A Prospective Pilot Study. <i>Blood</i> , 2018, 132, 4843-4843.	0.6	1
48	Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12*. <i>Leukemia and Lymphoma</i> , 2017, 58, 64-69.	0.6	11
49	Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD. <i>Annals of Hematology</i> , 2017, 96, 805-815.	0.8	12
50	Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2017, 130, 267-270.	0.6	255
51	Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. <i>Blood</i> , 2017, 129, 3175-3183.	0.6	126
52	Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2607-2614.	0.6	16
53	Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma. <i>Drugs</i> , 2017, 77, 1645-1655.	4.9	5
54	Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. <i>Blood</i> , 2017, 130, 1800-1808.	0.6	1,084

#	ARTICLE	IF	CITATIONS
55	The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. <i>Leukemia and Lymphoma</i> , 2017, 58, 1358-1365.	0.6	35
56	The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma. <i>Blood</i> , 2016, 127, 2093-2100.	0.6	25
57	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1283-1294.	5.1	818
58	Gamma Delta T Cell Subset V Gamma 2+ Expansion Associated with Longterm Infliximab Treatment in a Patient with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2016, 43, 2079.2-2082.	1.0	3
59	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. <i>Journal of Clinical Oncology</i> , 2016, 34, 3733-3739.	0.8	586
60	Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. <i>Lancet Oncology</i> , The, 2016, 17, 164-173.	5.1	283
61	Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study. <i>Blood</i> , 2016, 128, 1108-1108.	0.6	25
62	Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1110-1110.	0.6	35
63	Chromosome 9p24.1/PD-L1/PD-L2 Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). <i>Blood</i> , 2016, 128, 2923-2923.	0.6	5
64	Is Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab Naïve Patients?. <i>Blood</i> , 2016, 128, 1795-1795.	0.6	0
65	Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. <i>Blood</i> , 2016, 128, 690-690.	0.6	1
66	A Single-Center Retrospective Study of 140 Patients with Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplantation. <i>Blood</i> , 2016, 128, 4227-4227.	0.6	0
67	Preliminary Results of FDG-PET Scanning after GDP Chemotherapy Prior to Autologous Stem Cell Transplant (ASCT) for Relapsed/Refractory (RR) Lymphoma. <i>Blood</i> , 2016, 128, 4645-4645.	0.6	0
68	Failure to Achieve CR with First-Line Treatment Is the Primary Cause of Treatment Failure in T-Cell Lymphoma: The Princess Margaret Cancer Centre Experience. <i>Blood</i> , 2016, 128, 3005-3005.	0.6	1
69	Treatment Outcome of North American Patients with Adult T-Cell Leukemia/Lymphoma: Princess Margaret Cancer Centre Experience. <i>Blood</i> , 2016, 128, 3010-3010.	0.6	0
70	A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001. <i>Blood</i> , 2016, 128, 1849-1849.	0.6	0
71	Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. <i>Blood</i> , 2015, 126, 733-738.	0.6	39
72	Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 627-634.e5.	0.2	6

#	ARTICLE	IF	CITATIONS
73	Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e73-e81.	0.2	11
74	A Canadian Evidence-Based Guideline for the First-Line Treatment of Follicular Lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 59-74.	0.2	17
75	Predictors of the Trajectory of Neurocognitive Functioning in the First Six Months after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3289-3289.	0.6	1
76	Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2015, 126, 3983-3983.	0.6	5
77	Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). <i>Blood</i> , 2015, 126, 3986-3986.	0.6	15
78	Enteropathy-Associated T-Cell Lymphoma: A Single Centre Experience. <i>Blood</i> , 2015, 126, 5057-5057.	0.6	0
79	Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis. <i>Leukemia and Lymphoma</i> , 2014, 55, 2502-2507.	0.6	31
80	Promising SINEs for Embargoing Nuclearâ€œCytoplasmic Export as an Anticancer Strategy. <i>Cancer Discovery</i> , 2014, 4, 527-537.	7.7	89
81	Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. <i>Journal of Clinical Oncology</i> , 2014, 32, 3490-3496.	0.8	358
82	Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1813-1818.	2.0	16
83	Incidence, Risk Factors, and Long-Term Outcomes of Sclerotic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1751-1757.	2.0	15
84	Validation of National Institutes of Health Global Scoring System for Chronic Graft-Versus-Host Disease (GVHD) According to Overall and GVHD-Specific Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 556-563.	2.0	38
85	Limited benefit of pentostatin salvage therapy for steroidâ€œrefractory grade <sc>III</sc>â€œ<sc>IV</sc> acute graftâ€œversusâ€œhost disease. <i>Clinical Transplantation</i> , 2013, 27, 930-937.	0.8	11
86	Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 1164-1171.	0.8	92
87	Autologous Stem Cell Transplantation in Follicular Lymphoma: a Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2012, 104, 18-28.	3.0	74
88	Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy. <i>Haematologica</i> , 2012, 97, 751-757.	1.7	23
89	Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset of Chronic Gvhd. <i>Blood</i> , 2012, 120, 4184-4184.	0.6	0
90	How I treat relapsed and refractory Hodgkin lymphoma. <i>Blood</i> , 2011, 117, 4208-4217.	0.6	126

#	ARTICLE	IF	CITATIONS
91	Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. <i>Haematologica</i> , 2010, 95, 1496-1502.	1.7	16
92	Mocetinostat (MGCD0103), An Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, Produces Clinical Responses In Relapsed/Refractory Hodgkin Lymphoma (HL): Update From a Phase II Clinical Study. <i>Blood</i> , 2010, 116, 1763-1763.	0.6	7
93	Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592). <i>Blood</i> , 2010, 116, 284-284.	0.6	9
94	Comparing MicroRNA Expression In Aggressive and Indolent Non-Hodgkin Lymphomas Identifies a Prognostic Signature for Mantle Cell Lymphoma. <i>Blood</i> , 2010, 116, 800-800.	0.6	0
95	Autologous Stem Cell Transplantation for Adolescents and Young Adults with Relapsed and Refractory Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 2402-2402.	0.6	1
96	Standard therapy of advanced Hodgkin lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 497-506.	0.9	60
97	A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. <i>Hematology</i> , 2006, 11, 25-29.	0.7	19
98	Outcomes of Salvage Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B Cell Lymphoma (PMLCL) Are Inferior to Diffuse Large B Cell Lymphoma (DLBCL).. <i>Blood</i> , 2005, 106, 2085-2085.	0.6	1
99	Addition of Rituximab to CHOP Is an Attractive Strategy as Primary Therapy for Diffuse Large B Cell Lymphoma (DLBCL) in Patients Age <60 Years: An Economic Analysis.. <i>Blood</i> , 2004, 104, 3126-3126.	0.6	5